Effects of 18α-glycyrrhizin on TGF-β1/Smad signaling pathway in rats with carbon tetrachloride-induced liver fibrosis

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 2, 2015, Pages 1292-1301

  Qu, Ying ^a   Zong, Lei ^a   Xu, Mingyi ^a   Dong, Yuwei ^a   Lu, Lungen ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

18 glycyrrhizin; Collagen; Liver fibrosis; Smad; TGF 1

Indexed keywords

18ALPHA-GLYCYRRHETINIC ACID; CARBON TETRACHLORIDE; GLYCYRRHETINIC ACID; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; LIVER; LIVER CIRRHOSIS; MALE; METABOLISM; PATHOLOGY; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; CARBON TETRACHLORIDE; GLYCYRRHETINIC ACID; LIVER; LIVER CIRRHOSIS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84928103136     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Pellicoro A, Ramachandran P and Iredale JP. Reversibility of liver fibrosis. Fibrog Tiss Rep 2012; 5: S26.
2. Elsharkawy AM, Oakley F and Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005; 10: 927-939.
3. Jäättelä M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene 2004; 23: 2746-2756.
4. Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172.
5. Ferrucci LM, Bell BP, Dhotre KB, Manos MM, Terrault NA, Zaman A, Murphy RC, VanNess GR, Thomas AR and Bialek SR. Complementary and alternative medicine use in chronic liver disease patients. J Clin Gastroenterol 2010; 44: e40.
6. Nissar AU, Farrukh MR, Kaiser PJ, Rafiq RA, Afnan Q, Bhushan S, Adil HS, Subhash BC and Tasduq SA. Effect of N-acetyl cysteine (NAC), an organosulfur compound from Allium plants, on experimentally induced hepatic prefibrogenic events in wistar rat. Phytomedicine 2013; 20: 828-833.
7. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM; Ghany MG; HALT-C Trial Group. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2008; 47: 605-612.
8. Wang R, Kong J, Wang D, Lien LL and Lien EJ. A survey of Chinese herbal ingredients with liver protection activities. Chin Med 2007; 2: 5.
9. Luk JM, Wang X, Liu P, Wong KF, Chan KL, Tong Y, Hui CK, Lau GK and Fan ST. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int 2007; 27: 879-890.
10. Sato H, Goto W, Yamamura JI, Kurokawa M, Kageyama S, Takahara T, Watanabe A and Shiraki K. Therapeutic basis of glycyrrhizin on chronic hepatitis B. Antiviral Res 1996; 30: 171-177.
11. Ashfaq UA, Masoud MS, Nawaz Z and Riazuddin S. Glycyrrhizin as antiviral agent against Hepatitis C Virus. J Transl Med 2011; 9: 10.1186.
12. Adianti M, Aoki C, Komoto M, Deng L, Shoji I, Wahyuni TS, Lusida MI, Fuchino H, Kawahara N and Hotta H. Anti-hepatitis C virus compounds obtained from Glycyrrhiza uralensis and other Glycyrrhiza species. Microbiol Immunol 2014; 58: 180-187.
13. Orlent H, Hansen BE, Willems M, Brouwer JT, Huber R, Kullak-Ublick GA, Gerken G, Zeuzem S, Nevens F and Tielemans W. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol 2006; 45: 539-546.
14. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ and Reed MW. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Analytic Biochem 2000; 285: 194-204.
15. Lin Y, Xie WF, Chen YX, Zhang X, Zeng X, Qiang H, Chen WZ, Yang XJ, Han ZG and Zhang ZB. Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes. Liver Int 2005; 25: 796-807.
16. Nguyen J, Tang SY, Nguyen D and Alliston T. Load regulates bone formation and Sclerostin expression through a TGFβ-dependent mechanism. PLoS One 2013; 8: e53813.
17. Pessah M, Marais J, Prunier C, Ferrand N, Lallemand F, Mauviel A and Atfi A. c-Jun associates with the oncoprotein Ski and suppresses Smad2 transcriptional activity. J Biol Chem 2002; 277: 29094-29100.
18. Poncelet AC and Schnaper HW. Sp1 and Smad proteins cooperate to mediate transforming growth factor-beta 1-induced alpha 2 (I) collagen expression in human glomerular mesangial cells. J Biol Chem 2001; 276: 6983-6992.
19. Presser LD, McRae S and Waris G. Activation of TGF-β1 promoter by hepatitis C virus-induced AP-1 and Sp1: role of TGF-β1 in hepatic stellate cell activation and invasion. PLoS One 2013; 8: e56367.
20. Cassiman D, Libbrecht L, Desmet V, Denef C and Roskams T. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol 2002; 36: 200-209.
21. Gomes LR, Terra LF, Wailemann RA, Labriola L and Sogayar MC. TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer 2012; 12: 26.
22. Marek B, Kajdaniuk D, Mazurek U, Janczewska-Kazek E, Kos-Kudla B, Strzalka B, Fila A, Niedziolka D, Beniowski M and Ostrowska Z. TGF-β1 mRNA expression in liver biopsy specimens and TGF-β1 serum levels in patients with chronic hepatitis C before and after antiviral therapy. J Clin Pharm Ther 2005; 30: 271-277.
23. Castilla A, Prieto J and Fausto N. Transforming Growth Factors β1 and a in Chronic Liver Disease Effects of Interferon Alfa Therapy. N Engl J Med 1991; 324: 933-940.
24. Ueberham E, Löw R, Ueberham U, Schönig K, Bujard H and Gebhardt R. Conditional tetracycline-regulated expression of TGF-β1 in liver of transgenic mice leads to reversible intermediary fibrosis. Hepatology 2003; 37: 1067-1078.
25. Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said HM, Lorenzen J, Ten Dijke P and Gressner AM. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003; 125: 178-191.
26. Uemura M, Swenson ES, Gaça MDA, Giordano FJ, Reiss M and Wells RG. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and a-smooth muscle actin organization. Mol Biol Cell 2005; 16: 4214-4224.
27. Dooley S and ten Dijke P. TGF-β in progression of liver disease. Cell Tissue Res 2012; 347: 245-256.
28. Liu X, Hu H and Yin JQ. Therapeutic strategies against TGF-β signaling pathway in hepatic fibrosis. Liver Int 2006; 26: 8-22.
29. Saitoh M, Nishitoh H, Amagasa T, Miyazono K, Takagi M and Ichijo H. Identification of important regions in the cytoplasmic juxtamembrane domain of type I receptor that separate signaling pathways of transforming growth factor-beta. J Biol Chem 1996; 271: 2769-2775.
30. Matsuzaki K. Smad phosphoisoform signals in acute and chronic liver injury: similarities and differences between epithelial and mesenchymal cells. Cell Tissue Res 2012; 347: 225-243.
31. Mehra A and Wrana JL. TGF-β and the Smad signal transduction pathway. Biochem Cell Biol 2002; 80: 605-622.
32. A Briones-Orta M, C Tecalco-Cruz A, Sosa-Garrocho M, Caligaris C and Macías-Silva M. Inhibitory Smad7: emerging roles in health and disease. Curr Mol Pharmacol 2011; 4: 141-153.
33. Liu C, Gaca MD, Swenson ES, Vellucci VF, Reiss M and Wells RG. Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent. J Biol Chem 2003; 278: 11721-11728.
34. Schnabl B, Kweon YO, Frederick JP, Wang XF, Rippe RA and Brenner DA. The role of Smad3 in mediating mouse hepatic stellate cell activation. Hepatology 2001; 34: 89-100.
35. Liu Q, Wang X, Zhang Y, Li CJ, Hu LH and Shen X. Leukamenin F suppresses liver fibrogenesis by inhibiting both hepatic stellate cell proliferation and extracellular matrix production. Acta Pharmacol Sin 2010; 31: 839-848.
36. Weng H, Mertens PR, Gressner AM and Dooley S. IFN-γ abrogates profibrogenic TGF-β signaling in liver by targeting expression of inhibitory and receptor Smads. J Hepatol 2007; 46: 295-303.
37. Ka SM, Yeh YC, Huang XR, Chao TK, Hung YJ, Yu CP, Lin TJ, Wu CC, Lan HY and Chen A. Kidney-targeting Smad7 gene transfer inhibits renal TGF-β/MAD homologue (SMAD) and nuclear factor κB (NF-κB) signalling pathways, and improves diabetic nephropathy in mice. Diabetologia 2012; 55: 509-519.
38. Dooley S, Hamzavi J, Ciuclan L, Godoy P, Ilkavets I, Ehnert S, Ueberham E, Gebhardt R, Kanzler S, Geier A, Breitkopf K, Weng H and Mertens PR. Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology 2008; 135: 642-659.
39. Inoue Y and Imamura T. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci 2008; 99: 2107-2112.
40. Milanini J, Viñals F, Pouysségur J and Pagès G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J Biol Chem 1998; 273: 18165-18172.
41. Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD, Neve R and Ratan RR. Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci 2003; 23: 3597-3606.
42. Mann DA and Smart DE. Transcriptional regulation of hepatic stellate cell activation. Gut 2002; 50: 891-896.
43. Zhang W, Oul J, Inagaki Y, Greenwel P and Ramirez F. Synergistic cooperation between Sp1 and Smad3/Smad4 mediates transforming growth factor beta1 stimulation of alpha 2 (I)-collagen (COL1A2) transcription. J Biol Chem 2000; 275: 39237-39245.
44. Li L, Artlett CM, Jimenez SA, Hall DJ and Varga J. Oct Positive regulation of human alpha 1 (I) collagen promoter activity by transcription factor Sp1. Gene 1995; 164: 229-234.
45. Zong L, Qu Y, Xu MY, Dong YW and Lu LG. 18α-glycyrrhetinic acid down-regulates expression of type I and III collagen via TGF-β1/Smad signaling pathway in human and rat hepatic stellate cells. Int J Med Sci 2012; 9: 370.